Taj Pharma Announces Appointment of CFO — Shantanu Singh

Pharmaceutical Veteran Mr. Shantanu Singh Assumes CFO Taj Pharma as additional charge. End Quote

(1888PressRelease) November 01, 2018 - Taj Pharma Inc. (“Taj Pharma” or the “Company”) (TSXV: TPL, an emerging Indian pharmaceutical company, announced today that its board of directors (the “Board”) has accepted the appointment of Mr. Shantanu Kumar Singh New Chief Financial Officer (CFO) of the Company, effective July 26, 2018, as he has decided to take additional opportunities.

Mr. Shantanu Kumar(Shan) Singh has been appointed by the Board as the new CFO, effective August 1, 2018. Mr. Shantanu Singh is currently the Executive Director of Inovm pharma Inc. and most recently was the CEO of xenon-nanodrugs GmbH, based in Munich, Germany. Prior to that he was the Executive Director of Taj Pharmaceuticals, and has over 10 years business experience that includes senior leadership roles at Taj Ago, Taj Api, Morgan Stanley and Deutsche Bank.

Mr. Abhishek Singh, CEO of Taj Pharma said, “The Board is very thankful to Mr. Ahluwalia for his exemplary service to the Company and wishes him much success in his future endeavors. On behalf of the Board I would also like to welcome Mr.Shantanu Singh to the team and we look forward to working with him as he brings his extensive experience and knowledge to the Company.”

Taj Pharma also announced today that it has authorized the grant of an aggregate of 400,000 stock options (each an “Option”) to certain directors and officers of the Company and its subsidiaries in accordance with the Company’s stock option plan. Each Option will be exercisable into one common share of the Company at the closing market price of the Company’s common shares on the date of grant, for a period of five years from the date of grant. The issuance of the Options is subject to the approval of the TSX Venture Exchange.

About Taj Pharma
Taj Pharma is an emerging Indian pharmaceutical company focused on the development and commercialization of effective and affordable cancer therapeutics in the Russia and North American markets. The Company has recently acquired two generic drugs marketed in the United Kingdom, Capecitabine and Temozolomide. Furthermore, Taj Pharma has filed for marketing approval in selected countries of the EU and with the United States FDA for two additional high value generic oncology drugs and is currently evaluating other products, in different stages of development. Taj Pharma is committed to providing patients with affordable prescription medicines that lower healthcare costs and provide a better quality of life.

###

space

Other Related Press Releases